Strategic and Tactical Competitive Insights
We deliver crucial insights that empower clients to make winning strategic decisions.
Our consulting uncovers threats/opportunities, empowering clients to make strategic decisions that yield winning outcomes.
We deliver evidence-based recommendations, informed by expert interviews, to help clients address issues across:
- Asset Clinical Development and Commercialization
- R&D and Pipeline Assets
- Market Access
- Pricing/Reimbursement
- Regulatory Needs
- Emerging Markets
- Biosimilars/Generics
- OTC Offerings
- Digital Health
We provide decision support across the product lifecycle:
- New Product Planning
- Brand Planning
- Mature Product Planning
Our research capabilities are bolstered by in-house experts and a network spanning:
- Oncology/Hematology (solid/liquid tumors etc.)
- Gene and Cell Therapy / Rare Diseases (muscular dystrophy, ophthalmology, hemophilia etc.)
- Inflammatory and Autoimmune Diseases (including rheumatology, dermatology, allergy, MS etc.)
- Neurological Disorders (including epilepsy, Alzheimer’s, schizophrenia, PD etc.)
- Respiratory Disorders (including asthma, COPD, IPF, PAH etc.)
- Cardiovascular Disorders / Diabetes (including stroke, lipid disorders etc.)
- Infectious Diseases / Vaccines (including HIV, HCV, flu, MRSA, RSV etc.)
- Pain (including chronic pain, cancer-associated pain etc.)
- Blood Disorders (e.g. hemophilia)
With timely insights across therapy areas, we equip clients to accelerate competitive advantage.
Ready to build winning competitive strategies?
Let’s accelerate your success together. Contact us at info@lqventures.com.
December 11, 2025
Cell and Gene Therapy Video Recap—December 11, 2025
December 11, 2025
Cell and Gene Therapy Today—December 11, 2025
December 11, 2025
Rare Disease Today—December 10, 2025
December 11, 2025
Cardiovascular Today—December 10, 2025
December 11, 2025
Lucid Diligence Brief: EpilepsyGTx $33m Series A
December 10, 2025
Immunology Today—December 10, 2025
December 10, 2025
Women’s Health Video Recap—December 10, 2025
December 10, 2025
Neuroscience Video Recap—December 10, 2025
December 10, 2025
Neuroscience Today — December 10, 2025
December 10, 2025
Lucid Diligence Brief: SanegeneBio RNAi $110 million Series B
December 9, 2025
ESMO Immuno-Oncology 2025 Preview: Key Highlights to Watch
December 9, 2025